OMNICELL, INC.
TraceLink and Omnicell (OMCL) integrated their DSCSA compliance solution into hospital pharmacy operations, aiming to streamline medication verification and traceability. The integration is expected to reduce manual effort and improve efficiency for hospitals and health systems.
Omnicell (OMCL) shares fell 20.1% over four weeks. The company reported Q2 2026 adjusted EPS of $0.94, up 108.9% y/y, and revenue of $312.2M, up 7.4%. Omnicell raised 2026 non-GAAP EPS to $2.15-$2.30 and EBITDA to $175-$185M, but expects $6M incremental memory-chip costs, weaker product bookings ($425-$560M) and lower annual recurring revenue ($660-$680M).
Omnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.
Over the past 7 days, alphai's AI scored 1 news story mentioning OMCL (OMNICELL, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OMCL coverage spans earnings, financial news and technology.
In the last 30 days, OMCL insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($114K). The most active reporter was Njoku Nnamdi, President & COO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Potential boost to Omnicell's product offering and market appeal in hospital pharmacy automation.
Guidance is up, but margin headwinds and delayed bookings/ARR reduce near-term confidence, keeping downside risk elevated despite valuation support.
Guidance miss after an earnings beat is likely to pressure near-term estimates and keep the stock volatile.
The print is a mixed earnings outcome: upside on EPS and revenue beat, but weaker sequential revenue guidance likely drives near-term downside risk.
Guidance raise plus improved profitability metrics (GAAP and non-GAAP) can re-rate near-term expectations for OMCL’s earnings power.
alphai scores every news story that mentions OMCL with an AI model for sentiment and relevance, and aggregates insider trades from OMNICELL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TraceLink and Omnicell (OMCL) integrated their DSCSA compliance solution into hospital pharmacy operations, aiming to streamline medication verification and traceability. The integration is expected to reduce manual effort and improve efficiency for hospitals and health systems.
2 min readOmnicell (OMCL) shares fell 20.1% over four weeks. The company reported Q2 2026 adjusted EPS of $0.94, up 108.9% y/y, and revenue of $312.2M, up 7.4%. Omnicell raised 2026 non-GAAP EPS to $2.15-$2.30 and EBITDA to $175-$185M, but expects $6M incremental memory-chip costs, weaker product bookings ($425-$560M) and lower annual recurring revenue ($660-$680M).
6 min readOmnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.
4 min readOmnicell (NASDAQ:OMCL) reported Q2 CY2026 revenue of $312.2 million, up 7.4% year on year and 0.6% above Wall Street estimates, and non-GAAP EPS of $0.94, above consensus. For next quarter, it guided revenue to $304 million, below estimates, and guided weaker EPS. The stock fell 5.6% to $39.08.
3 min readOMNICELL, INC. (OMCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Omnicell, Inc. David Unger 4220 North Freeway Vice President, Investor Relations Fort Worth, TX 76137 ir@omnicell.com Omnicell Announces Second Quarter 2026 Financial Results Omnicell delivers solid second quarter 2026 financial results Updates full year 202
6 min readOmnicell (NASDAQ: OMCL) is set to report Q2 earnings Thursday. The article notes Omnicell previously beat revenue expectations with $309.9 million revenue, up 14.9% YoY, and exceeded EPS estimates, with next-quarter EBITDA guidance above analysts’ expectations. For the upcoming quarter, analysts expect revenue up 6.8% YoY.
3 min readOMNICELL, INC. (OMCL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000926326 0000926326 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repo
2 min readVanguard Capital Management has disclosed beneficial ownership of 2,274,766 shares of Omnicell (NASDAQ: OMCL) common stock, representing a 5% stake. This filing, a Schedule 13G, indicates a passive investment rather than an intent to influence the company. Vanguard holds sole dispositive power over all these shares and sole voting power over 340,249 shares.
2 min readOmnicell Inc (OMCL) shares fell 3.0% to $34.40. The company is considered undervalued by 9.3% based on its GF Value™ of $37.91, yet its GF Score™ of 79/100 suggests above-average quality. Despite the undervaluation, its current P/E ratio of 860.0x is significantly higher than its 5-year median, and insiders have sold $0.4 million worth of shares recently, with no reported buying, indicating a cautious outlook.
3 min readOmnicell, Inc. CEO Randall A. Lipps reported the vesting of 79,494 performance-based restricted stock units (RSUs) after the company met specific stock performance objectives. In connection with this vesting, 15,642 shares were withheld for tax liabilities at $34.40 per share. Following these transactions, Lipps directly holds 444,592 Common Stock shares, with additional shares held indirectly in trusts.
2 min read
